Buerger’s Disease (BD) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Buerger’s Disease (BD) or Thromboangiitis obliterans (TAO) is a nonatherosclerotic, segmental inflammatory disease that most commonly affects the small and medium-sized arteries and veins in the upper and lower extremities. In the characteristic acute-phase lesion, in association with occlusive cellular thrombosis, the acute inflammation involving all layers of the vessel wall led TAO to be classified as a vasculitis. There is no consistent pattern in HLA haplotypes among patients with Buerger’s disease. However, in the European nations, there was a preponderance of HLA-A9 and HLA-B5 antigens.

The acute-phase lesion is characterized by acute inflammation involving all coats of the vessel wall, especially of the veins, in association with occlusive thrombosis.

Intermediate phase in which there is a progressive organization of the occlusive thrombus in the arteries and veins. Chronic phase or end-stage lesion is characterized by organization of the occlusive thrombus with extensive recanalization, prominent vascularization of the media, and adventitial and perivascular fibrosis.

In the year 2019, the overall incidence of cases of Buerger’s disease is reported to be 12.5 to 28 cases per 100,000 population in the USA, however, the numbers are high in European and APAC populations.

 

The competitive landscape of Buerger’s Disease (BD) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Buerger’s Disease (BD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Buerger’s Disease (BD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Buerger’s Disease (BD)  – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          AMB-301          Ambulero Inc.   Phase 1

2          Allogeneic Mesenchymal Stem Cells      Stempeutics Research Pvt Ltd       Phase 2

3          CLBS12            Caladrius Biosciences, Inc.        Phase 2

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033